Barenholz Yechezkel Projects

Results Found (7)
Technology NameBriefcaseLead Researcher
At a Glance Ayana Pharma is uniquely positioned to expand the uses and efficacy of the lipid-based cytotoxic drug’s well-established clinical profile. Invented by Prof. Yechezkel Barenholtz from the Hebrew University who is also the co-founder ...
More
Barenholz Yechezkel
Background Current preclinical and clinical data indicate that there is negligible release of drug from circulating liposomes. Once liposomes extravagate to extracellular tissue fluids, little is known of the processes determining drug release. ...
More
Barenholz Yechezkel
Category Life Sciences and Bio Technology    Keywords Chemotherapy, Drug resistance * The project is conducted in collaboration with Memorial Sloan-Kettering Cancer Center. Application Cells with multidrug resistance (MDR) due to aberrant ...
More
Barenholz Yechezkel
Company Name LipoCure Year Company was founded 2009 Company Founders Prof. Yechezkel Barenholtz Current CEO Dr. Liana Patt, Ph. D., MBA About the Company LipoCure is developing a number of highly-potent therapeutics utilizing proprietary ...
More
Barenholz Yechezkel
Background Intravenous injection of some liposomal drugs, diagnostic agents, micelles and other lipid-based nanoparticles cause hypersensitivity reactions in up to 45% of patients,which appear to be initiated by the complement system (C) of ...
More
Barenholz Yechezkel
Background Most active pharmaceutical ingredients (APIs) are not suitable for “passive” loading into nano-liposomes. The desired concentration in the nano-liposomes is hard to achieve. Consequently, the therapeutic efficacy in humans is not ...
More
Goldblum Amiram
Background The physical size of protein drugs and their susceptibility to degradation are key determinates that make them more dependent on drug delivery technologies. However formulating protein delivery systems so that they maintain their ...
More
Barenholz Yechezkel